EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 366 filers reported holding EXELIXIS INC in Q1 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $9,775,911 | -1.8% | 435,065 | +3.7% | 0.49% | +5.9% |
| Q1 2024 | $9,954,308 | -1.3% | 419,482 | -0.2% | 0.46% | -10.2% |
| Q4 2023 | $10,083,837 | -0.5% | 420,335 | -9.3% | 0.51% | -4.8% |
| Q3 2023 | $10,131,277 | +17.3% | 463,674 | +2.6% | 0.54% | +16.0% |
| Q2 2023 | $8,635,408 | -9.4% | 451,879 | -8.0% | 0.46% | -11.8% |
| Q1 2023 | $9,536,618 | +15.2% | 491,325 | -4.8% | 0.52% | +19.6% |
| Q4 2022 | $8,276,175 | +29.4% | 515,971 | +26.5% | 0.44% | +21.6% |
| Q3 2022 | $6,394,000 | -24.7% | 407,750 | -0.1% | 0.36% | -20.0% |
| Q2 2022 | $8,495,000 | -8.7% | 408,019 | -0.5% | 0.45% | +5.6% |
| Q1 2022 | $9,300,000 | +22.4% | 410,218 | -1.3% | 0.43% | +25.6% |
| Q4 2021 | $7,601,000 | -33.1% | 415,818 | -22.6% | 0.34% | -34.6% |
| Q3 2021 | $11,356,000 | +67.5% | 537,162 | +44.4% | 0.52% | +61.0% |
| Q2 2021 | $6,780,000 | -23.7% | 372,120 | -5.4% | 0.32% | -30.4% |
| Q1 2021 | $8,888,000 | – | 393,453 | – | 0.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
| GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
| Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
| CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
| EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
| CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
| Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
| Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |